These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35287177)

  • 21. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
    Hampel H; Bürger K; Teipel SJ; Bokde AL; Zetterberg H; Blennow K
    Alzheimers Dement; 2008 Jan; 4(1):38-48. PubMed ID: 18631949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach.
    Begcevic I; Brinc D; Brown M; Martinez-Morillo E; Goldhardt O; Grimmer T; Magdolen V; Batruch I; Diamandis EP
    J Proteomics; 2018 Jun; 182():12-20. PubMed ID: 29684683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Injury markers predict time to dementia in subjects with MCI and amyloid pathology.
    van Rossum IA; Vos SJ; Burns L; Knol DL; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; L'italien G; van der Flier WM; Teunissen CE; Blennow K; Barkhof F; Rueckert D; Wolz R; Verhey F; Visser PJ
    Neurology; 2012 Oct; 79(17):1809-16. PubMed ID: 23019259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anosognosia Is an Independent Predictor of Conversion From Mild Cognitive Impairment to Alzheimer's Disease and Is Associated With Reduced Brain Metabolism.
    Gerretsen P; Chung JK; Shah P; Plitman E; Iwata Y; Caravaggio F; Nakajima S; Pollock BG; Graff-Guerrero A;
    J Clin Psychiatry; 2017; 78(9):e1187-e1196. PubMed ID: 29022655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.
    Kester MI; Teunissen CE; Sutphen C; Herries EM; Ladenson JH; Xiong C; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    Alzheimers Res Ther; 2015 Sep; 7(1):59. PubMed ID: 26383836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways.
    Maruyama M; Matsui T; Tanji H; Nemoto M; Tomita N; Ootsuki M; Arai H; Sasaki H
    Arch Neurol; 2004 May; 61(5):716-20. PubMed ID: 15148149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
    J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
    Kester MI; Teunissen CE; Crimmins DL; Herries EM; Ladenson JH; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Nov; 72(11):1275-80. PubMed ID: 26366630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. APOEɛ4-TOMM40L Haplotype Increases the Risk of Mild Cognitive Impairment Conversion to Alzheimer's Disease.
    Cardoso R; Lemos C; Oliveiros B; Almeida MR; Baldeiras I; Pereira CF; Santos A; Duro D; Vieira D; Santana I; Oliveira CR
    J Alzheimers Dis; 2020; 78(2):587-601. PubMed ID: 33016906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic classification of mild cognitive impairment and Alzheimer's disease: MRI independent component analysis.
    Willette AA; Calhoun VD; Egan JM; Kapogiannis D;
    Psychiatry Res; 2014 Nov; 224(2):81-8. PubMed ID: 25194437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival Analysis in Cognitively Normal Subjects and in Patients with Mild Cognitive Impairment Using a Proportional Hazards Model with Extreme Gradient Boosting Regression.
    Khajehpiri B; Moghaddam HA; Forouzanfar M; Lashgari R; Ramos-Cejudo J; Osorio RS; Ardekani BA;
    J Alzheimers Dis; 2022; 85(2):837-850. PubMed ID: 34864679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of Plasma Neurofilament Light Chain and Mini-Mental State Examination Score Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease within 5 Years.
    Darmanthé N; Tabatabaei-Jafari H; Cherbuin N;
    J Alzheimers Dis; 2021; 82(3):951-964. PubMed ID: 34120902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease.
    Duits FH; Brinkmalm G; Teunissen CE; Brinkmalm A; Scheltens P; Van der Flier WM; Zetterberg H; Blennow K
    Alzheimers Res Ther; 2018 Jan; 10(1):5. PubMed ID: 29370833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD.
    Tramutola A; Triplett JC; Di Domenico F; Niedowicz DM; Murphy MP; Coccia R; Perluigi M; Butterfield DA
    J Neurochem; 2015 Jun; 133(5):739-49. PubMed ID: 25645581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile.
    Winston CN; Goetzl EJ; Akers JC; Carter BS; Rockenstein EM; Galasko D; Masliah E; Rissman RA
    Alzheimers Dement (Amst); 2016; 3():63-72. PubMed ID: 27408937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamics of the "Cognitive" Brain Wave P3b at Rest for Alzheimer Dementia Prediction in Mild Cognitive Impairment.
    Porcaro C; Vecchio F; Miraglia F; Zito G; Rossini PM
    Int J Neural Syst; 2022 May; 32(5):2250022. PubMed ID: 35435134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.